NEULASTA (pegfilgrastim) – a leukocyte growth factor that is commonly used to decrease the incidence of infection in patients receiving myelosuppressive anti-cancer drugs. FDA approved uses: Neulasta is indicated to decrease the incidence of infection, as manifested by febrile neutropenia, in patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a clinically significant incidence […]
COPAXONE (glatiramer acetate) – a biologic immune modifier that is commonly used to treat multiple sclerosis (MS). Glatiramer is thought to act by modifying immune processes that believed to be responsible for the pathogenesis of MS. FDA approved uses: Copaxone is indicated for reduction of the frequency of relapses in patients with Relapsing-Remitting Multiple Sclerosis, […]
REMICADE (infliximab) – a biologic anti-inflammatory agent that binds specifically to TNF-alpha and blocks its interaction with the p75 cell surface TNF receptor. TNF is a naturally occurring cytokine that is involved in normal inflammatory and immune responses. Elevated levels of TNF are found in the synovial fluid of patients with RA, JIA, PsA, and […]
ENBREL (etanercept) – a biologic anti-inflammatory agent that binds specifically to TNF-alpha and blocks its interaction with the p75 cell surface TNF receptor. TNF is a naturally occurring cytokine that is involved in normal inflammatory and immune responses. Elevated levels of TNF are found in the synovial fluid of patients with RA, JIA, PsA, and […]